Scott Jeffers
Directeur Technique/Scientifique/R&D chez GENSIGHT BIOLOGICS S.A.
Profil
Scott Jeffers is currently the Chief Technical Officer at Gensight Biologics SA since 2022.
Previously, he worked as the Director-Gene Therapy at Selecta Biosciences, Inc. and as the VP-CMC Process Development & Manufacturing at Redpin Therapeutics, Inc. Dr. Jeffers completed his undergraduate degree at Colorado State University and holds a doctorate from Purdue University.
Postes actifs de Scott Jeffers
| Sociétés | Poste | Début |
|---|---|---|
| GENSIGHT BIOLOGICS S.A. | Directeur Technique/Scientifique/R&D | 01/04/2022 |
Anciens postes connus de Scott Jeffers
| Sociétés | Poste | Fin |
|---|---|---|
| CARTESIAN THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Redpin Therapeutics, Inc.
 Redpin Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Redpin Therapeutics, Inc. operates as a biotechnological platform which enables targeted regulation of neuronal activity in brain to achieve treatment and control of CNS circuit and other disorders. The company was founded by Elma S. Hawkins, Jeffrey Friedman, Scott Sternson Michael Kaplitt, Sarah Stanley and Jonathan Dordick in 2017 and is headquartered in New York, NY. | Corporate Officer/Principal | - |
Formation de Scott Jeffers
| Purdue University | Doctorate Degree |
| Colorado State University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| GENSIGHT BIOLOGICS S.A. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Redpin Therapeutics, Inc.
Redpin Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Redpin Therapeutics, Inc. operates as a biotechnological platform which enables targeted regulation of neuronal activity in brain to achieve treatment and control of CNS circuit and other disorders. The company was founded by Elma S. Hawkins, Jeffrey Friedman, Scott Sternson Michael Kaplitt, Sarah Stanley and Jonathan Dordick in 2017 and is headquartered in New York, NY. | Commercial Services |
Selecta Biosciences, Inc.
 Selecta Biosciences, Inc. BiotechnologyHealth Technology Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its portfolio includes pipeline, autoimmune, gene therapy, and biologic therapy. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian on December 10, 2007 and is headquartered in Watertown, MA. | Health Technology |